Immunotherapeutic Effects of β-D Mannuronic Acid on IL-4, GATA3, IL-17 and RORC Gene Expression in the PBMC of Patients with Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) are chronic relapsing immune-mediated disorders that result from an aberrant immunological response. IBD comprises of Crohn's disease (CD) and ulcerative colitis (UC). The precise aetiology of IBD has not been fully understood, however, recent studies support the hypothesis that patients with IBD have a dysregulated immune response to endogenous bacteria in the gastrointestinal tract (GIT). The increasing number of hospitalisation coupled with the high economic burden faced by IBD patients, calls for more concerted research efforts, to design a potent and credible treatment option for these strata of patients. This research was designed to test the efficacy and potency of β-D Mannuronic acid (M2000) in the treatment of IBD. Ten ml of blood was aseptically collected from 24 IBD patients and 24 normal controls. PBMC was isolated and stimulated with 1 µg/mL of LPS and incubated for 4 hours. The cells were later treated with 10 µg/mL or 50 µg/mL of Mannuronic acid and incubated for 24 hours at 370C under 5% CO2 and 100% humidity. After the incubation, RNA was extracted from the cells, cDNA was synthesised, and the expression of the gene was evaluated using quantitative real-time PCR. The result indicated a significant down-regulation of RORC and IL-17 genes expression, while the expression of IL-4 and GATA3 genes were significantly up-regulated. These research findings have shown that M2000 a biocompatible agent, that has an immunotherapeutic, immunomodulatory and immunosuppressive effects on the PBMC of IBD patients.
1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006; 12(30):4807-12.
2. Podolsky DK. The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2002; 16(6):933-43.
3. Michener WM, Whelan G, Greenstreet RL, Farmer RG. Comparison of the clinical features of Crohn's disease and ulcerative colitis with onset in childhood or adolescence. Cleve Clin Q 1982; 49(1):13-6.
4. Fuss IJ, Neurath M, Boirivant M, Klein JS, De La Motte C, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157(3):1261-70.
5. Bamias G, Nyce MR, Sarah A, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005; 143(12):895-904.
6. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21(1):685-711.
7. Kohu K, Ohmori H, Wong WF, Onda D, Wakoh T, Kon S, et al. The Runx3 transcription factor augments Th1 and down-modulates Th2 phenotypes by interacting with and attenuating GATA3. J Immunol 2009; 183(12):7817-24.
8. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126(6):1121-33.
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64(5):625-39.
10. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 2005.
11. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123(4):1006-12.
12. Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci 2012; 37(1):106-26.
13. Fatemeh H,Hadi H,Ahmad MS,Farhad JN,Seyed Ehsan E,Mohammed FJ, Ali A Mirshafiey A.Targeting crosstalk between tumor and tumor microenvironment by β-D mannurinic acid (M2000) in murine breast cancer model.Cancer medicine 2017; 6(3). http://doi.org/10.1002 /cam4.1013
14. Mirshafiey A, Rehm B, Abhari RS, Borzooy Z, Sotoude M, Razavi A. Production of M2000 (β-D-mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol 2007; 24(1):60-6.
15. Mirshafiey A, Rehm B, Sotoude M, Razavi A, Abhari RS, Borzooy Z. Therapeutic approach by a novel designed an anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis. Immunopharmacol Immunotoxicol 2007; 29(1):49-61.
16. Mirshafiey A, Cuzzocrea S, Rehm B, Matsuo H. M2000: a revolution in pharmacology. Med Sci Monit 2005; 11(8): PI53-PI63.
17. Mirshafiey A, Matsuo H, Nakane S, Rehm BH, Koh C-S, Miyoshi S. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol Immunotoxicol 2005; 27(2):255-65.
18. Mirshafiey A, Cuzzocrea S, Rehm B, Mazzon E, Saadat F, Sotoude M. Treatment of experimental arthritis with M2000, a novel designed a non-steroidal anti-inflammatory drug. Scand J Immunol 2005; 61(5):435-41.
19. Mirshafiey A, Khorramizadeh MR, Saadat F, Rehm BH. Chemopreventive effect of M2000, a new anti-inflammatory agent. Med Sci Monit 2004; 10(10):PI105-PI9.
20. Fattahi MJ, Abdollahi M, Agha Mohammadi A, Rastkari N, Khorasani R, Ahmadi H, et al. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol 2015; 37(6):535-40.
21. Nielsen OH, Ciardelli T, Wu Z, Langholz E, Kirman I. Circulating soluble interleukin-2 receptor α and β chain in inflammatory bowel disease. Am J Gastroenterol 1995; 90(8):1301-6.
22. Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai Ti, Morohashi T, et al. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis 2009; 15(3):328-34.
23. Karttunnen R, Breese E, Walker-Smith J, MacDonald T. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J Clin Pathol 1994; 47(11):1015-8.
24. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998; 22(4):382-9.
25. Khan MM, Chatterjee S, Dwivedi VP, Pandey NK, Singh Y, Tousif S, et al. CD4+ T cell-derived novel peptide Thp5 induces interleukin-4 production in CD4+ T cells to direct T helper 2 cell differentiation. J Biol Chem 2012; 287(4):2830-5.
26. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351(25):2599-610.
27. Skapenko A, Leipe J, Niesner U, Devriendt K, Beetz R, Radbruch A, et al. GATA-3 in human T cell helper type 2 development. J Exp Med 2004; 199(3):423-8.
28. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, et al. A validated regulatory network for Th17 cell specification. Cell 2012; 151(2):289-303.
29. Shen W, Durum SK. The synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. Neurochem Res 2010; 35(6):940-6.
30. Mangan PR, Harrington LE, O'quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 2006; 441(7090):231-4.
31. Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 2009; 137(5):1736-45.
32. Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009; 206(3):525-34.
33. Aletaha S, Haddad L, Roozbehkia M, Bigdeli R, Asgary V, Mahmoudi M, et al. M2000 (β‐D‐Mannuronic Acid) as a Novel Antagonist for Blocking the TLR2 and TLR4 Downstream Signalling Pathway. Scand J Immunol 2017; 85(2):122-9.
34. Burgler S, Mantel P-Y, Bassin C, Ouaked N, Akdis CA, Schmidt-Weber CB. RORC2 is involved in T cell polarization through interaction with the FOXP3 promoter. J Immunol 2010; 184(11):6161-9.
35. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 2002; 295(5553):338-42.